Sugi Predict

Sugi Predict / Compounds / SCHEMBL22199724

SCHEMBL22199724

SCHEMBL22199724

CCCC[C@H]1C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@@H](CCN=[N+]=[N-])C(N)=O)CSCC(=O)NC(Cc2ccc(O)cc2)C(=O)N(C)[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CN)C(=O)N[C@@H](CC(C)C)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc2csc3ccccc23)C(=O)N1C

nearest known ligand 0.62

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ CD274 Q9NZQ7 9/20 0.62
▸ PDCD1 Q15116 7/20 0.59
▸ CIB1 Q99828 4/20 0.47
▸ KLKB1 P03952 4/20 0.46
▸ PRLHR P49683 1/20 0.45
▸ F12 P00748 1/20 0.43
▸ EPHA2 P29317 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20013161 0.96 CD274 (0.56) CD274PDCD1CIB1KLKB1PRLHR
SCHEMBL22199471 0.93 CD274 (0.63) CD274PDCD1CIB1KLKB1PRLHR
SCHEMBL20013216 0.93 CD274 (0.63) CD274PDCD1CIB1KLKB1PRLHR
SCHEMBL22199723 0.93 CD274 (0.58) CD274PDCD1CIB1KLKB1PRLHR
SCHEMBL16140549 0.93 CD274 (0.71) CD274PDCD1CIB1KLKB1F12
SCHEMBL18254661 0.92 CD274 (0.69) CD274PDCD1CIB1KLKB1F12
SCHEMBL16140558 0.92 CD274 (0.69) CD274PDCD1CIB1KLKB1F12
SCHEMBL17811159 0.91 CD274 (0.73) CD274PDCD1CIB1KLKB1F12
SCHEMBL17811129 0.91 CD274 (0.72) CD274PDCD1CIB1KLKB1
SCHEMBL17811175 0.91 CD274 (0.66) CD274PDCD1CIB1KLKB1F12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11358988-B2 Immunomodulators BRISTOL-MYERS SQUIBB COMPANY (US) 2022-06-14 — — US disclosed
US-20200216498-A1 IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2020-07-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11358988-B2 Immunomodulators CD74, ICOS, HAVCR2 CD274 36/4885PDCD1 79/4885CIB1 1031/4885
US-20200216498-A1 IMMUNOMODULATORS CD74, ICOS, HAVCR2 CD274 36/4885PDCD1 79/4885CIB1 1031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.